Harry Teichtahl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Harry Teichtahl has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
David Wang
Senior Scientific Officer, The University of Sydney, Woolcock Institute of Medical Research, Department of Respiratory & Sleep Medicine, Royal Prince Alfred Hospital, Missenden Road, Camperdown, Sydney, NSW 2050, Australia
3 shared publicationsIan Kronborg
3 shared publicationsDavid Cunnington
2 shared publicationsGaye Cherry
2 shared publications- Olaf Heino Drummer
Department of Forensic Medicine, Monash University, Melbourne, Victoria, Australia
2 shared publications Andy Prodromidis
Drug and Alcohol Service, Western Hospital, Melbourne, Australia
1 shared publication
Latest Publications
- 30 October 2007
- Published by Informa Healthcare in Expert Opinion on Drug Safety
- Vol. 6 (6) , 641-649
Sleep-disordered breathing with chronic opioid use
(2007). Sleep-disordered breathing with chronic opioid use. Expert Opinion on Drug Safety: Vol. 6, No. 6, pp. 641-649.
- 30 October 2007
- Published by Informa Healthcare in Expert Opinion on Drug Safety
- Vol. 6 (6) , 641-649
Sleep-disordered breathing with chronic opioid use
(2007). Sleep-disordered breathing with chronic opioid use. Expert Opinion on Drug Safety: Vol. 6, No. 6, pp. 641-649.
- 1 September 2003
- Published by Elsevier in Sleep Medicine
- Vol. 4 (5) , 419-425
Scoring polysomnography respiratory events: the utility of nasal pressure and oro-nasal thermal sensor recordings
- 1 September 2003
- Published by Elsevier in Sleep Medicine
- Vol. 4 (5) , 419-425
Scoring polysomnography respiratory events: the utility of nasal pressure and oro-nasal thermal sensor recordings
Sleep‐disordered breathing in stable methadone programme patients: a pilot study
Aims. To explore the possibility that stable MMP patients have sleep‐disordered breathing (SDB) and abnormal sleep architecture defined by nocturnal sleep stages and sleep efficiency. Design. Observational. Setting. Regional Methadone Service and sleep disorders laboratory in a university affiliated hospital. Participants and measurements. Ten stable MMP patients and nine normal subjects were assessed clinically and with overnight polysomnography. Findings. There were no differences in age, sex and body mass index between the groups. The methadone dose ranged between 50 and 120 mg/day. Six patients had central apnoea index (CAI) greater than 5, four had a CAI greater than 10 and three of these exhibited periodic breathing. No normal subject had central sleep apnoea. The patients had lower sleep efficiency ( p < 0.05), less slow wave sleep ( p < 0.01), less rapid eye movement sleep ( p < 0.05) and more Stage 2 sleep ( p < 0.05) than controls. Conclusions. Stable MMP patients have more sleep architecture abnormalities than controls and a higher prevalence of central sleep apnoea. Further studies are needed to confirm these findings, to delineate the mechanisms for the abnormalities and to assess whether the SDB is related to sudden death in stable MMP patients. We recommend that MMP patients have awake and sleep respiration assessed to identify those potentially at risk.
Sleep‐disordered breathing in stable methadone programme patients: a pilot study
Aims. To explore the possibility that stable MMP patients have sleep‐disordered breathing (SDB) and abnormal sleep architecture defined by nocturnal sleep stages and sleep efficiency. Design. Observational. Setting. Regional Methadone Service and sleep disorders laboratory in a university affiliated hospital. Participants and measurements. Ten stable MMP patients and nine normal subjects were assessed clinically and with overnight polysomnography. Findings. There were no differences in age, sex and body mass index between the groups. The methadone dose ranged between 50 and 120 mg/day. Six patients had central apnoea index (CAI) greater than 5, four had a CAI greater than 10 and three of these exhibited periodic breathing. No normal subject had central sleep apnoea. The patients had lower sleep efficiency ( p < 0.05), less slow wave sleep ( p < 0.01), less rapid eye movement sleep ( p < 0.05) and more Stage 2 sleep ( p < 0.05) than controls. Conclusions. Stable MMP patients have more sleep architecture abnormalities than controls and a higher prevalence of central sleep apnoea. Further studies are needed to confirm these findings, to delineate the mechanisms for the abnormalities and to assess whether the SDB is related to sudden death in stable MMP patients. We recommend that MMP patients have awake and sleep respiration assessed to identify those potentially at risk.